Dow Jones
35 950,89 +520,47 (+1,47 %) Nasdaq
14 226,22 -32,27 (-0,23 %) Nikkei 225
33 496,15 +9,26 (+0,03 %) EUR/USD
1,0908 +0,0014 (+0,13 %) HANG SENG
16 925,85 -117,03 (-0,69 %) Bitcoin EUR
35 058,25 +181,38 (+0,52 %)
MRK Jan 2025 95.000 call
| Clôture précédente | 13,20 |
| Ouverture | 13,55 |
| Offre | 14,35 |
| Vente | 15,65 |
| Prix d’exercice | 95,00 |
| Date d’expiration | 2025-01-17 |
| Var. jour | 13,55 - 13,55 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 117 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
